Le Lézard
Classified in: Health, Business
Subject: TNM

Medical Assets Acquisition Announced by TheraLight, LLC


LINDON, Utah, March 12, 2020 /PRNewswire/ -- TheraLight, LLC, an FDA-registered manufacturer and distributor of cutting-edge light therapy products, recently announces it has acquired the assets from Theralight, Inc., a manufacturer of phototherapy devices. The assets acquisition includes a portfolio of products, trademarks, and FDA 510k clearances. Theralight, Inc. was privately owned and founded in July 2000 with operations from facilities located in Carlsbad, California. The company created the first hands-free, light therapy system and had the single worldwide license from Osram Sylvania to Icetron lamp technology for the treatment of skin disorders.

"We are pleased to acquire the assets from the owners of Theralight, Inc.," stated Charles Vorwaller, president & CEO. "This acquisition provides us an opportunity to expand our company in a number of new ways, including the addition of the DuaLight and VersaClear products. There are many advantages to these non-laser products over competitors that sell Excimer lasers. The good news is that these treatments are covered by insurance companies."

In 2002, Theralight, Inc. received US FDA 510(k) clearance to market its desktop UV120-2 UVA/UVB phototherapy system for treating psoriasis, vitiligo, eczema, and seborrhoeic dermatitis. Weighing less than 20lbs, the product was the first targeted phototherapy system to emit either UVA or UVB bands of ultra-violet light, providing physicians with the flexibility of treating patients using either PUVA (UVA with psoralen), or UVB.

"As a company, we remain committed to delivering innovation and world class technology designed to provide positive outcomes for both medical professional and their patients," noted According to Justin Vorwaller, MBA, COO of TheraLight, LLC, 

This acquisition transaction was advised and handled through Thorpe North & Western's David W. Osborne, a registered patent attorney; TheraLight, LLC plans to integrate the acquired assets in quarter two of 2020.

To learn more about TheraLight, LLC, please visit www.theralight.com.

About TheraLight, LLC
TheraLight, LLC is a medical device company and emerging global leader in innovative photomedicine technology. Representing management with over 30 of experience, TheraLight delivers expertise in design, manufacturing, production, and regulatory compliance. We partner with healthcare professionals to bring the best and newest technology, as well as provide advanced training and support to maximize clinical and financial outcomes. TheraLight was founded by the management team at Aspen Laser Systems, LLC. For more information about TheraLight, LLC, please visit www.theralight.com.

Media Contact:
TheraLight, LLC
Brian Probst
801.376.8469
[email protected] 

SOURCE TheraLight, LLC


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: